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Summary. The Gittins index provides a well established, computationally attractive, optimal solution to a class of resource
allocation problems known collectively as the multi-arm bandit problem. Its development was originally motivated by the
problem of optimal patient allocation in multi-arm clinical trials. However, it has never been used in practice, possibly
for the following reasons: (1) it is fully sequential, i.e., the endpoint must be observable soon after treating a patient,
reducing the medical settings to which it is applicable; (2) it is completely deterministic and thus removes randomization
from the trial, which would naturally protect against various sources of bias. We propose a novel implementation of the
Gittins index rule that overcomes these diﬃculties, trading oﬀ a small deviation from optimality for a fully randomized,
adaptive group allocation procedure which oﬀers substantial improvements in terms of patient beneﬁt, especially relevant
for small populations. We report the operating characteristics of our approach compared to existing methods of adaptive
randomization using a recently published trial as motivation.
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1. Introduction
Consider a clinical trial to test the eﬀectiveness of several
treatments on a group of patients. A rational observer, who
is unfamiliar with established medical convention, might well
suppose that patients would be allocated to treatments with
the aim of optimizing their collective health. Indeed, using
this idea as the initial motivation, Gittins and Jones (1979)
ﬁrst proposed an optimal, deterministic rule to perform such
a task within a multi-arm clinical trial, which is termed the
Gittins index. Since then, the Gittins index and its exten-
sions have been extensively used to address resource allo-
cation problems (collectively known as “multi-arm bandit”
models) in a variety of scientiﬁc ﬁelds. Applications include:
queuing theory and optimal scheduling (Aalto et al., 2009),
computer-communication networks (Cechi and Jacko, 2013)
and internet marketing (Hauser et al., 2009), among others.
A large body of literature has accumulated on the use of
bandit models to address ethical issues in trial design (see
e.g., Berry and Fristedt, 1985; Berry and Eick, 1995; Press,
2009). Ironically, bandits, and more speciﬁcally the Gittins
index, have never been used in clinical practice (to the best
of the authors’ knowledge) due to certain realities of medical
research. These are discussed at length in a recent review
by Villar et al. (2015), the main ﬁndings of which are now
summarized.
The most immediate limitation is practical: in order to
apply the Gittins index each patient’s outcome needs to be
observed before the next patient is assigned. This rules out the
vast majority of medical conditions and diseases where the
outcome of treatment is observed with non-negligible delay.
Another major barrier, common to all optimal decision–
analytical designs (Cheng and Berry, 2007), is that the
deterministic nature of the Gittins index runs contrary to
the predominant mode of clinical trial design and analysis
over the last 60 years. Under this framework patients are ran-
domized to diﬀerent treatment arms with equal probability.
This has several desirable consequences. First, it guarantees
(asymptotically) that patient groups will be balanced with
respect to all characteristics (known or unknown), thus re-
ducing the potential for confounding bias. Second, it provides
a perfect vehicle to facilitate a double-blind experiment,
making it harder for the trial organizers to induce allocation
bias (see e.g., Chow and Chang, 2008). Third, ﬁxed and equal
randomization maximizes the learning about all treatments,
i.e., it maximizes power to detect a signiﬁcant diﬀerence
between any two treatments in the trial by assigning similar
numbers of patients to both. Having a high power is usually
the primary aim of a trial and relegates the beneﬁt to patients
(within the trial) into second place. However, there are signs
that this established view, as summarized in the Belmont
report (Beauchamp, 2008), is changing. It is now not as
common in rare disease settings, for example in pediatric
oncology (Wang and Arnold, 2002).
The reduction in statistical power caused by adaptive allo-
cation is not unique to these index rules, rather it aﬀects all
adaptive allocation procedures to a greater or lesser extent
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(Hu and Rosenberger, 2003). It is simply not possible to si-
multaneously maximize trial power while maximizing patient
outcomes by skewing treatment allocation. That is why an
ideal adaptive design would seek to assign more patients to
the better treatment with the minimum sacriﬁce of inferential
power.
In a multi-arm setting in which several treatments are
assessed simultaneously against a shared control group, adap-
tive randomization does not face the power–patient beneﬁt
trade-oﬀ as separate two-arm trials do. The power of an
adaptive multi-arm design can be increased by protecting the
allocation to the control treatment (Trippa et al., 2012). By
incorporating this feature, as shown in Villar et al. (2015), one
can identify adaptive trial designs that score highly in both
statistical power and patient beneﬁt. Moreover, by testing
many new promising treatments at the same time, multi-arm
trials increase the probability of ﬁnding a successful new
treatment and speed up the process of doing so.
This article addresses the remaining two limitations, i.e.,
its determinism and its fully sequential nature. We present
an implementation of the Gittins index that introduces ran-
domization, trading oﬀ a small amount of its optimality to
gain applicability to real clinical trials. This is achieved by
a modiﬁed algorithm that is probabilistic and is applied to
blocks of patients rather than individuals, as suggested by
Rosenberger and Lachin (1993).
One of the ﬁrst works on randomized bandits was Yang and
Zhu (2002). The authors consider a multi-arm problem with
covariates and introduce a myopic randomized solution that
is asymptotically consistent. Instead, we consider a problem
without covariates and concentrate on introducing random-
ization to the Gittins index, by taking into account future se-
quences of allocations under Gittins’ rule. Our simple, heuris-
tic approach thereby aims to achieve a near-optimal mean
total rewards criterion in a computationally feasible way.
The closest idea we know of in the literature is in Cheng and
Berry (2007), where the introduction of randomization into an
optimal design is considered. Treatment decisions are made
using a decision–analytic approach whose goal is to maximize
overall successful patient treatment over the patient popula-
tion under the constraint that each arm must have at least
probability r of being assigned to patients in the trial. Our
algorithm does not impose any limitation on the allocation
probabilities. This allows for arms to be dropped or promoted
within a trial if there is enough evidence.
In Section 2, we introduce the Gittins index and demon-
strate how it can be applied in a clinical trial setting with a
binary outcome. We introduce our probabilistic implementa-
tion of the Gittins index, which we call the forward looking
Gittins index (FLGI), in Section 3. In Section 4, we compare
our approach to alternative procedures by performing sim-
ulations in the context of a recently published clinical trial:
NeoSphere, (Gianni et al., 2012). We conclude with a discus-
sion of our results and point to future research in Section 5.
2. Methods: the Gittins Index
Consider a clinical trial to test the eﬀectiveness of K experi-
mental treatments against a control treatment on a ﬁxed sam-
ple of T patients. When a patient t (t = 1,...,T ) is allocated to
treatment k (k = 0, . . . , K), where k = 0 denotes the control,
then a binary outcome Yk,t is observed with Pr(Yk,t = 1) =
pk, the true unknown response probability for treatment k.
Assume that Yk,t=1 if the treatment is successful and 0 other-
wise. Patients enter the trial one-by-one and the outcome for
patient t is observed before patient t + 1 appears.
Let each parameter pk be assigned a Beta(sk,0,fk,0) prior
density at the start of the trial, where sk,0 and fk,0 denote
prior beliefs about the relative chances of success and fail-
ure of treatment k respectively. Given the conjugacy of the
prior- and Bernoulli-distributed outcome, these priors are
converted into Beta posteriors for pk via Bayes theorem as
patients enter the trial, which are assigned to a treatment
arm and subsequently experience a success or a failure. Let
Xk,t = (sk,0 + Sk,t, fk,0 + Fk,t) be the two state-vector of avail-
able information on treatment k at time t, where the random
vector (Sk,t, Fk,t) represents the number of successful and un-
successful outcomes for arm k up to patient t. The posterior for
pk after having treated patient t and observing sk,t successes
and fk,t failures is f (pk|xk,t) ∼ Beta(sk,0 + sk,t ,fk,0 + fk,t) with
its posterior mean being E[pk|xk,t ] = sk,t+sk,0sk,t+fk,t+sk,0+fk,0 . Finally,
let ak,t be the binary indicator variable denoting whether pa-
tient t + 1 is assigned to treatment k or not. The multi-armed
bandit optimization problem is to ﬁnd an allocation rule π
such that:
V ∗D(x˜0) = max
π∈
Eπ
[(
T−1∑
t=0
K∑
k=0
dtE[pk|xk,t ]ak,t
)∣∣∣x˜0,
]
. (1)
where x˜0 = (xk,0)Kk=0 is the initial joint state with all the prior
parameters, Eπ[·] denotes expectation under allocation rule
π, and d is a discount factor (i.e., 0 ≤ d < 1) introduced for
reasons of tractability so that a trial of inﬁnite size (T = ∞)
can be assumed. Thus, V ∗D(x˜0) is the optimal expected total-
discounted value function conditional x˜0 over , the family
of admissible allocation rules (i.e., those for which it holds
that
∑K
k=0 ak,t = 1 for all t). Put simply, (1) is the maximum
average (discounted) number of patients responses attainable
given the initial information on the available treatments be-
fore the start of the trial.
Since rewards are geometrically discounted, i.e., patient t’s
success yields a reward of dt , the choice of d plays a fundamen-
tal role. To see this, interpret d as the probability of the trial
continuing after a given patient, so that (1 − dt) is the prob-
ability of a trial terminating after patient t. If d is small (say
0.5), then optimization is done for an small expected number
of patients (say 15, since (1 − 0.5)15 < 10−4). An index for
the undiscounted ﬁnite horizon problem can be considered,
though it introduces further complexities (Villar et al., 2015).
The solution to (1) can be found via dynamic program-
ming, using a backward induction algorithm. This becomes
computationally infeasible for relatively small values of T and
K and is extremely diﬃcult to implement in practice, since it
speciﬁes an arm to use in each possible trial accumulated his-
tory. An elegant and computationally tractable solution to (1)
when considered for T = ∞ was given by Gittins and Jones
(1979). They showed that the optimal rule obtained by back-
ward induction is equivalent to the rule of allocating patient
t + 1 to the arm with the highest Gittins index at time t. For
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treatment k, this is denoted G(xk,t) where:
G(xk,t) = sup
τ≥1
E
[(
τ−1∑
i=0
E[pk|xk,t+i]di
)
|xk,t
]
E
[(
τ−1∑
i=0
di
)
|xk,t
] . (2)
Gittins and Jones (1979) proved that one can attach an
index G(xk,t) to each treatment k, which depends only on its
current information state, such that the optimal action for
patient i is to be allocated to the treatment whose current in-
dex is greatest. The Gittins index is calculated by solving the
problem of allocating patients optimally between treatment k
and a known treatment which yields a constant reward. Cal-
culations of the indices (2) have been reported in tables as in
Gittins et al. (2011). A detailed explanation of how the Git-
tins index rule is deployed and a table with values are given
in Tables 4 and 5 of Web Appendix A.
3. The Forward-Looking Gittins
Index Algorithm
Assume that instead of enrolling T patients one-by-one, pa-
tients are enrolled in groups of size b over J stages, so that
J × b = T . We wish to specify a rule based on the Gittins in-
dex that sequentially randomizes the next b patients among
the K + 1 treatments at stage j (j=1,...,J) given the data
up to block j − 1. This translates to determining πk,j, where:
πk,j = the probability of allocation to treatment k at stage
j (j = 1, . . . , J), which is common to all patients in block j,
when using the Gittins index and given all data observed up
to the stage j-1 (and therefore patient (j − 1) × b) , denoted
by x˜(j−1)b. Note that x˜(j−1)b can be written as a (K + 1) × 2
matrix in which row k represents the parameters of treatment
k’s current posterior distribution up to patient (j − 1)b. This
marginal probability is obtained via the following formula:
πk,j = 1
b
jb∑
t=(j−1)b+1
[ ∑
x˜t−1∈t−1
Pr(aGIk,t = 1|X˜t−1 = x˜t−1)
×Pr(X˜t−1 = x˜t−1|X˜(j−1)b = x˜(j−1)b)
]
(3)
Here t−1 represents the set of all possible values for
X˜t−1 given initial data x˜(j−1)b for every future patient t in
(j − 1)b + 1, . . . , jb under the Gittins index rule (summarized
by aGIk,t ). Each term of the summation within the square brack-
ets of equation (3) represents the joint probability of allocat-
ing a future patient t in block j to treatment k and the current
information state at patient t − 1, given the data at the be-
ginning of block j − 1. Notice that
 For the initial stage, i.e., for j = 1, x˜(j−1)b contains only the
prior beliefs on the eﬀectiveness of each treatment. When
all treatments are assigned identical priors, it is clear that
πk,j=
1
K+1 for all k. This is proved in Web Appendix B.
aGI1,3 = 1
G1(1,1) = 0.8699
G0(2, 2) = 0.7844
aGI0,4 = 1
G1(1, 2) = 0.7005
G0(2,2) = 0.7844
1
2
Y
2,0 = 0
aGI1,4 = 1
G1(2,1) = 0.9102
G0(2, 2) = 0.7844
1
2
Y2,0
= 1
Figure 1. The FLGI rule and a probability tree of all trial
histories using the Gittins rule when K = 2, b = 2, and x˜2 =
[(2, 2); (1, 1)]. Bold text indicates the allocated treatment un-
der the Gittins index rule {aGIk,t }. Gittins index values used
correspond to d = 0.99 (See Table 4 in Web Appendix A).
 For j ≥ 2, the allocation decision for the ﬁrst patient in
block j (i.e., for patient t = (j − 1)b + 1) is deterministic
if a single treatment has a unique maximum Gittins index
given x˜(j−1)b. However, if multiple treatments k∗ ∈ {0, ..., K}
are joint maxima, ties are broken at random among the k∗.
 For j ≥ 2 and for subsequent patients in block j (t =
(j − 1)b + 2, ..., jb), allocation probabilities are determined
by averaging over the posterior predictive distribution of fu-
ture data given x˜(j−1)b. For Bernoulli data and Beta-prior,
this is the well known Beta-Binomial distribution. Again,
ties between treatments are broken at random.
3.1. Worked Example
To clarify how these probabilities are computed and their
computational cost, we present a simple example of a two-
arm trial testing a control treatment (k=0) against an exper-
imental treatment (k=1) with a block of size 2 (i.e., b = 2
and K = 2). Suppose further that in the ﬁrst block of the
trial, having started with Beta(1,1) priors, the resulting allo-
cation was, two patients to control—one success and another
one a failure—and no patient to the experimental treatment.
Therefore, for the second block the priors for each treatment
are x˜2 = [(2, 2); (1, 1)].
Figure 1 illustrates, via a probability tree, how the FLGI
probabilities for block 2 given the data in block 1 are com-
puted. Given that the experimental treatment would have the
maximum Gittins index, the allocation decision for the ﬁrst
patient of the second block (i.e., patient 3) is deterministic.
It follows that Pr(aGI0,3 = 1|x˜2) = 0 and Pr(aGI1,3 = 1|x˜2) = 1.
When the second patient of the second block is to be allo-
cated (i.e., patient 4), given that we have allocated the exper-
imental treatment to the ﬁrst patient, two possible outcomes
can occur. If a success occurs, which happens with prob-
ability 1/2 = 0.5, then the experimental treatment is allo-
cated again. If a failure occurs, then the control treatment is
allocated. Hence, Pr(aGIk,4 = 1|x˜2) =
∑
x˜3∈3 Pr(a
GI
k,4 = 1|X˜3 =
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Table 1
Comparison of the mean value of successes under the
optimal rule for K = 2, b = 2 (obtained via dynamic
programming), ﬁxed randomized (FR), the FLGI, and the GI
(Gittins index) in 103 replicas of a trial of size T = 30. The
discount factor used for GI and FLGI is d = 0.7 (so as to
get (1 − dT ≈ 0) when T = 30.)
Optimal FLGI
p = [p0 p1] FR (b = 2) (b = 2) GI (b = 1) pmax ∗ T
[0.1 0.1] 3.02 3.01 3.06 2.99 3
[0.2 0.9] 16.35 25.80 25.92 26.24 27
[0.1 0.3] 5.88 7.53 7.70 7.56 9
[0.35 0.65] 15.06 17.74 17.65 17.79 19.5
[0.4 0.5] 13.59 13.75 13.89 13.86 15
[0.7 0.8] 22.55 22.82 22.67 22.72 24
x˜3)Pr(X˜3 = x˜3|x˜2) reduces to 1/2 for k = 0, 1. Using equa-
tion (3), we can obtain π0,2 = (0 + 1/2)/2 = 1/4, π1,2 = (1 +
1/2)/2 = 3/4.
From this example, it is clear that the computational cost of
computing the πkj’s, which depends on the joint state for the
K + 1 arms, i.e., x˜t (instead of the one-arm state xt), will grow
exponentially as b and K increase. Hence, we use a Monte-
Carlo algorithm for this purpose.
The optimal allocation for any K, b, and T solves a
dynamic programming problem. To assess the FLGI’s perfor-
mance, we consider a two-arm trial of 30 patients recruited
in 15 separate blocks (T = 30, J = 15, b = 2, K = 2). The
optimal rule in this case allocates one patient per treatment
in the ﬁrst block and both patients to the treatment with
the highest posterior mean in the last block. For blocks
between 2 and 14, optimal actions are less straightforward to
summarize. The FLGI for b = 2 constitutes a heuristic that
approximates the optimal policy as shown in Table 1 (See
Web Appendix C for the problem formulation).
4. Simulation Study
We now evaluate the properties of the FLGI procedure by
simulation, focusing on its: statistical power (1 − β); type I
error rate (α); expected number of patients assigned to the
best treatment (p∗); and expected number of patient successes
(ENS). We compare the FLGI to the following established
group allocation procedures (see Table 2):
(1) Fixed randomization (FR): patients are allocated be-
tween the K experimental arms and the control arm
with a ﬁxed and equal probability at every interim
stage.
(2) Thompson sampling (TS): assuming a uniform prior on
[0, 1]K+1 for (p0, . . . , pk), following Thompson (1933),
we allocate treatment k to patients in block j with
a probability proportional to the posterior probability
that pk is the largest response rate given the observed
data.
(3) Trippa et al. procedure (TP): Trippa et al. (2012) pro-
posed a Bayesian adaptive design similar to Thompson
sampling for testing multiple experimental treatments
in a controlled trial setting for patients with recurrent
Glioblastoma. Although the original cancer setting de-
termined the use of a time-to-event outcome, the design
approach has been transferred to the binary data set-
ting (Wason and Trippa, 2014).
(4) Optimal allocation ratios: following the implementa-
tion in Tymofyeyev et al. (2007), we consider two
diﬀerent rules: Neyman allocation (NA), which mini-
mizes total sample sizes for a given power constraint,
and RSIHR allocation (RSIHRA), which minimizes ex-
pected failures given a power constraint and is named
after the authors that ﬁrst introduced it in a two-armed
setting (Rosenberger et al., 2001).
(5) Controlled FLGI (CFLGI): in addition to the rule de-
ﬁned by (3), we shall consider a controlled group al-
location rule which, similarly to the Trippa procedure,
protects the allocation to the control treatment, so it
never goes below 1/(K + 1) during the trial.
Note that in choosing which rules to compare our proce-
dure against, we wanted to include methods that are used in
practice, although ﬁxed randomization is still the most popu-
lar allocation rule in use. In all simulations, we used a uniform
Beta(1,1) prior for each treatment arm and we computed the
allocation probabilities for Thompson sampling, Trippa pro-
cedure, FLGI, and CFLGI using a simple Monte-Carlo ap-
proximation based on 102 replicas (Matlab code is available
with this article at the Biometrics website).
4.1. The NeoSphere Trial
The NeoSphere trial, as reported by Gianni et al. (2012),
evaluated the eﬀect of a combination of drugs on patho-
logical complete response in the breast for women with
locally advanced inﬂammatory breast cancer. Out of 417
eligible patients, 107 were randomly assigned to group 0
(trastuzumab plus docetaxel), 107 to group 1 (pertuzumab
and trastuzumab plus docetaxel), 107 to group 2 (pertuzumab
and trastuzumab), and 96 to group 3 (pertuzumab plus doc-
etaxel). The original trial allocated patients between the four
arms with a ﬁxed and equal randomization probability of 1/4.
The primary response outcome was available 24weeks after
randomization. At the end of the trial, the response rates ob-
served in groups 0, 1, 2 and 3 were 29.0%, 45.8%, 16.8%, and
24.0%, respectively.
We show the impact of redesigning the study using the
FLGI and the alternative patient allocation rules. Two re-
sponse rate scenarios are initially considered : (i) the global
null where pi = 0.290, i = 0, 1, 2, 3; (ii) the observed values
in NeoSphere, p0 = 0.290, p1 = 0.458, p2 = 0.168, and p3 =
0.240. We ﬁrst ﬁx the block size to b = 9 patients and the
number of interim analysis to J = 46. This leaves three re-
maining patients which are allocated using the probability
allocation vector resulting after observing the outcomes of
block 46. If we imagine that the trial’s duration remains ﬁxed
at 2 years, a block size of nine is consistent with being able
to observe the outcome after a 2week delay. We subsequently
review the method’s performance for larger block sizes which
are consistent with longer delays.
To assess the chance of a type I error being made under
the global null, we report the family-wise error rate α¯. This is
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Table 2
Allocation rules: deﬁnitions
Allocation rule Probability vectors
Fixed randomization (FR) πFRk,j = 1K+1
Thompson Sampling (TS) πTSk,j =
Pr(maxi pi=pk |x˜(j−1)b)c∑K
k=0 Pr(maxi pi=pk |x˜(j−1)b)
c
with c = j∗b
2T
Trippa et al. Procedure (TP) πTPk,j+1 = π¯k,j+1∑K
k=0 π¯k,j+1
,
where π¯k,j+1 = Pr(pk>p0|x˜(j−1)b)
γj∑K
k=1 Pr(pk>p0|x˜(j−1)b)
γj
k = 1, . . . , K
1
K
exp[max[(nk,j)
K
k=1] − n0,j]ηj k = 0
and as in Trippa et al. (2012)
γj = 10(j ∗ b/T )0.75 and ηj = 0.25(j ∗ b/T )
Optimal allocation ratios ρ∗k = n∗k/
∑K
k=0(n
∗
k)
where n∗k solve: minn0,...,nK
∑K
k=0 wknk
s.t nk ≥ B
∑K
k=0 nk ∀k
φ(n0, . . . , nK) ≥ C
Neyman allocation (NA) takes wk = 1 ∀k
RSIHR allocation (RSIHRA) takes wk = (1 − pk) ∀k
For both NA and RSIHRA, we considered B = 0.1 and C = 0.80
and deﬁned πk,j using an allocation function
controlled by a tuning parameter γ and a γ = 2, σ = 1
smoothing parameter σ. See equation (2) in Tymofyeyev et al. (2007)
Controlled FLGI (CFLGI) πCFLGIk,j =
π¯u
k,j∑K
k=0 π¯
u
k,j
, for k = 0, ..., K
where π¯u0,j = 1/K and for k = 1, . . . , K
with π¯uk,j are the approximate
FLGI probabilities in (3).
Modiﬁed controlled FLGI (MCFLGI) πMCFLGIk,j =
π¯u
k,j∑K
k=0 π¯
u
k,j
, for k = 0, ..., K
where π¯u0,j = max{1/K,min{π¯u0,j, (1 − 1/K)}},
with π¯uk,j are the approximate
FLGI probabilities in (3)
the probability of rejecting at least one true null hypothesis.
The Bonferroni method was used to account for multiple test-
ing and ensure that α¯ ≤ α, i.e., all hypothesis whose p-values
pk are less than pk ≤ αK are rejected (with α = 0.05). To as-
sess power, we calculate the probability of rejecting the null
for the truly best treatment under scenario (ii). That is the
probability of rejecting H01 : p0 = p1 when p1 = 0.458.
Hypothesis testing was performed using a normal cut-oﬀ
value (when appropriate) and using an adjusted version of
Fisher’s exact test for comparing two binomial distributions.
Fisher’s test is conservative, i.e., its actual rejection rate is
far below the nominal signiﬁcance level. To make the designs
comparable, we chose its cut-oﬀ value so as to achieve the
nominal type I error rate (Villar et al., 2015).
Under the global null, p∗ is deﬁned as the mean proportion
of patients assigned to the control group, whereas under the
alternative, p∗ is deﬁned as the mean proportion assigned
to treatment 1. We also report the ENS value if all patients
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Table 3
5 ∗ 103 replicas of the NeoSphere trial under a FR design and alternative group designs with block size b = 9 and trial size
T = 417. Top: Scenario (i). Middle: Scenario (ii) and Scenario (iii). Bottom: Scenario (iv).
H0 : p0 = pi = 0.29 for i = 1, . . . , 3
Scenario (i) α p∗ (s.e.) ENS (s.e.)
FR 0.043 0.250 (0.02) 120.88 (9.20)
TP 0.036 0.379 (0.05) 120.04 (9.24)
CFLGI 0.034 0.250 (0.02) 120.86 (9.22)
TS 0.054 0.250 (0.07) 120.86 (9.25)
RSIHR 0.024 0.248 (0.09) 120.80 (9.12)
NA 0.024 0.251 (0.09) 120.81 (9.30)
FLGI 0.046 0.251 (0.21) 120.96 (9.26)
GI 0.061 0.247 (0.23) 120.92 (9.49)
UB 1 120.93 (0.00)
p1 = [0.29 0.458 0.168 0.24]
Scenario (ii) (1 − β)H02 p∗ (s.e.) ENS (s.e.)
FR 0.642 0.250 (0.02) 120.62 (9.12)
TP 0.892 0.450 (0.04) 149.81 (10.9)
CFLGI 0.820 0.654 (0.06) 166.40 (11.9)
TS 0.782 0.585 (0.10) 155.93 (13.5)
RSIHR 0.480 0.479 (0.06) 139.51 (10.9)
NA 0.483 0.439 (0.05) 134.84 (10.0)
FLGI 0.178 0.847 (0.11) 179.64 (13.7)
GI 0.140 0.858 (0.12) 181.00 (14.1)
UB 1 190.99 (0.00)
p1 = [0.458 0.29 0.168 0.24]
Scenario (iii) (1 − β)H01 (1 − β)H02 p∗ (s.e.) ENS (s.e.)
FR 0.639 0.994 0.250 (0.02) 120.66 (9.17)
CFLGI 0.812 0.750 0.250 (0.02) 129.84 (11.2)
MCFLGI 0.878 0.728 0.382 (0.03) 140.69 (10.5)
RSIHR 0.493 0.960 0.480 (0.06) 139.47 (11.1)
NA 0.492 0.964 0.438 (0.06) 134.56 (10.3)
UB 1 190.99 (0.00)
p1 = [0.168 0.458 0.29 0.24]
Scenario (iv) (1 − β)H01 p∗ (s.e.) ENS (s.e.)
FR 0.994 0.250 (0.02) 120.36 (9.27)
CFLGI 0.987 0.634 (0.10) 152.85 (12.6)
RSIHR 0.961 0.480 (0.06) 139.65 (11.0)
NA 0.957 0.438 (0.06) 134.54 (10.3)
UB 1 190.99 (0.00)
received the best treatment (i.e., 0.458 ∗ T ) as an upper bound
on ENS of any design under scenario (ii).
4.2. Results
Table 3 displays the results from 5000 replications of the trial.
As expected, under scenario (i) (top of Table 3) all the designs
are equal in terms of ENS and p∗ (ENS is T × 0.29 = 120.93).
All rules allocate on average the same proportion of patients
to each treatment (close to 0.25). The exception to this is
Trippa procedure for which control group allocation is always
higher because it is matched to that of the best performing
(by chance) treatment. Thompson sampling and the Gittins
index-based designs have a variability in the allocation prob-
abilities between 4–8 times larger than the other designs.
The most interesting diﬀerences among these designs occur
under scenario (ii). The value of ENS attained under ﬁxed
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randomization in this case is close to the value reported in the
study (which was of 121 complete remissions). We ﬁnd that
the Gittins index, FLGI, and CFLGI procedures increase
the number of successes dramatically compared to ﬁxed
randomization (achieving 60, 58, and 45 more remissions
on average, respectively). Trippa procedure also improves
on ﬁxed randomization (by approximately 29 remissions on
average) and it achieves a higher power than the CFLGI, yet
remissions attained are 10% lower.
Of particular interest is the learn-versus-earn trade-oﬀ.
The ﬁrst four designs (ﬁxed randomization, Trippa procedure,
CFLGI, and Thompson sampling) achieve more than 60%
power to reject H01, whereas the last four designs (RSIHRA,
Neyman allocation, FLGI, and the Gittins index) fall below
this power level. However, the designs that achieve the highest
patient beneﬁt (i.e., p∗ ≥ 0.80 and ENS ≥ 175) are the ones
that have the lowest power. The designs that have higher ENS
and p∗ also have a larger variability of allocation probabilities.
The optimal allocation ratio designs (Neyman allocation
and RSIHRA) are constrained to attain at least a given prob-
ability to reject the global null for a test of homogeneity H0
(i.e., to reject at least one H0k with a two-sided test). In sce-
nario (ii), they are required to attain the same level as ﬁxed
randomization to do that (i.e., C = 0.80 in Table 2). In fact,
both designs produce levels substantially higher than that
(0.99 and 0.97, respectively). To attain this, both optimal
designs, after a minimal requirement of experimentation on
all arms (i.e., B = 0.1 × b), skew allocation toward the best
(i.e., k = 1) and worst arm (i.e., k = 2) to reject H12. Because
of this, their probability of rejecting H02 is lower than that of
ﬁxed randomization, as the increased probability to reject the
global null H0 is gained by increasing the chance of rejecting
H12 instead of H02.
For multi-arm trials, power depends on the particular al-
ternative hypothesis considered. In Neosphere, the worst and
best treatments were diﬀerent from the control arm and this
explains the reduced marginal power of Neyman allocation
and RSIHRA to reject H02. It also explains the high marginal
power attained by CFLGI, as its allocation quickly tends to
assigning one in every four patients to control and the remain-
ing three to the best experimental arm, which in Neosphere
was k = 2. To illustrate this point, we consider two more cases
where we compare the CFLGI to the optimal designs that tar-
get an ethical criterion and power simultaneously: Scenario
(iii), where we let the control arm be the best treatment ob-
served in Neosphere, and Scenario (iv) where control was as-
sumed to be the worst treatment in Neosphere.
These results suggest that the power–ENS balance of the
CFLGI is maintained except for the case in which the best
arm is the control arm. In general, we expect the CFLGI to
have a high marginal power to detect a diﬀerence between the
best experimental treatment, if it exists, and control. In Web
Appendix D, we discuss these extra scenarios and present a
modiﬁcation of the CFLGI rule that also performs well in the
case where control is the best treatment.
4.3. Varying Block Size
We next evaluate the eﬀect of changing the block size (or the
number of interim analyses) on the ENS–power relation of the
allocation methods in which power is not constrained.
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Figure 2. The expected number of successes (ENS) versus
power for diﬀerent designs: Thompson Sampling (TS), Trippa
et al. (TP), Fixed Randomized (FR), FLGI, and CFLGI and
block sizes b varying in {1, 5, 10, 25, 50, 90} in 104 replicas.
By deﬁnition when b = 1 the FLGI is identical to the fully
sequential Gittins index rule (i.e., it favors ENS at the expense
of power). Also, from Proposition 1 (see Web Appendix B) we
know that for b = T (and J = 1) and all arms with identical
initial priors, the FLGI group design is simply a ﬁxed ran-
domized design (i.e., it favors power at the expense of ENS).
Hence, by varying b between 1 and T one can see how the
FLGI approach trades oﬀ power for ENS within this range.
This is illustrated in Figure 2. Note that the trial size is in-
creased from 419 to 450 to allow several values of b to divide
it exactly.
For the FLGI design, as the size of the block increases,
its ENS decreases and its power increases. Conversely, for the
other designs (CFLGI and Trippa procedure), the balance be-
tween power and ENS remains approximately constant when
changing the block size. Block sizes with at least 80% power
have ENS values below 180, while block sizes with ENS values
above 180 have below 80% power. The designs that protect
the allocation to control have a very similar performance in
their power–ENS trade-oﬀ across diﬀerent block sizes. For ev-
ery block size, CFLGI achieves a higher ENS but a lower
power than Trippa procedure.
4.4. The FLGI and the Patient Population Size
Cheng and Berry (2007) argue that the optimality of a partic-
ular design should be judged by taking into account the size of
the trial (T ), the total patient population (N, or the “patient
horizon”) and, crucially, the ability of the trial’s allocation
rule to facilitate identiﬁcation of the truly best treatment at
its conclusion while treating patients in the trial as eﬀectively
as possible. We now assess, via simulation, the designs consid-
ered from this conceptual viewpoint by considering the total
expected number of successes (ENSN) as the sum of the ﬁrst T
patients in the trial (ENST ) and the remaining N − T outside
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of the trial (ENSN−T ):
ENSN = ENST + ENSN−T . (4)
We explore two rules to choose the ‘best’ treatment (de-
noted by k∗) at the end of the trial. Rule 1 is as follows: if
there is no treatment with a statistically signiﬁcant eﬀect com-
pared to the control group, then the control group is chosen
(k∗ = 0). However, if one or more treatment is signiﬁcantly ef-
fective, then the treatment with the largest posterior mean by
the end of the trial is chosen. ENSN in equation(4) can then
be evaluated for each allocation rule by calculating ENST as
described earlier in Section 4 and using
ENSN−T = (N − T )
K∑
k=0
Pr(k∗ = k)pk, (5)
where Pr(k∗ = k) is the probability treatment and k is selected
at the end of the trial. Rule 2 simply chooses the treatment
with the highest Gittins index by the end of the trial so that
ENSN−T = (N − T )
K∑
k=0
Pr
(
G(sk,T , fk,T ) = max
j
G(sj,T , fj,T )
)
pk
(6)
The probabilities of selecting a treatment as the best
treatment under both rules are computed via simulation af-
ter 103 replicas of the trial of size T . Let K=3 and the
true response rate vector be the observed values in Neo-
Sphere, i.e., (p0, p1, p2, p3) = (0.29,0.458,0.168,0.24). We con-
sider two possible trial sizes: a small trial (T = 80) to rep-
resent a rare disease and a large trial (the original size of
T=417) to represent a more common condition. Further-
more, we vary the population size as N = (1 + l)T for l ∈
{1, 2, 3, .., 10, 20, 40, 60, 80, 100}. This allows, in the rare dis-
ease case, for the total population to range from 160 (equal
numbers inside and outside of the trial) to 8080 (a hundred
times as many outside as inside). We assess the relative gap
between ENSN using its upper bound (if all patients had been
assigned to the best treatment from the start) and the value
calculated from equation (4) (for a given trial allocation and
treatment selection rule) using
Gap = Np1 − ENSN
Np1
. (7)
Figure 3 (top) shows the relative gap (7) as a function of
N under rule 1 for the small trial (top-left) and large trial
(top-right). These results indicate that all rules, except for
the Gittins index and FLGI, exhibit a type of asymptotic
convergence similar to the one reported in Cheng and Berry
(2007). That is, as the population that beneﬁts from the trial
grows (i.e., as N − T → ∞), their suboptimality gap tends
to zero. However, for FLGI and the Gittins index approach
the opposite is true. For smaller population sizes the gap is
smallest, and it grows as a function of N. Moreover, the gap
of the Gittins index and the FLGI rules is always above the
other designs.
The poor performance of the uncontrolled Gittins index-
based rules is caused by the use of a classical signiﬁcance test.
Such tests are appropriate when large enough numbers of pa-
tients are assigned to all arms and are thus perfectly suited
to rules such as ﬁxed randomization. If a truly best treatment
exists, the Gittins index-based rules will assign highly unequal
numbers across trial arms. Although this imbalance is a posi-
tive indicator of a superior treatment eﬀect, it (paradoxically)
leads to a low power. For this reason, Figure 3 (bottom) shows
how the relative gap of the Gittins index, FLGI, and CFLGI
decreases toward 0 under selection rule 2 for both trial sizes.
The results for the other allocation methods using selection
rule 1 are shown for comparison. Under rule 2, the conver-
gence of the gap toward 0 as T and N − T tend to inﬁnity
holds and moreover, the advantage of these rules over the
other designs holds for all N.
These results illustrate that, for rare diseases (where there
is little power to detect a statistically signiﬁcant treatment ef-
fect) bandit-based designs are highly attractive. Furthermore,
the value of such designs lies within the fact that they can
be eﬀectively used for treatment selection (i.e., using rule 2).
Note that CFLGI performs well under either selection rule.
5. Discussion
Despite its optimality, and its original clinical motivation, the
Gittins index rule has never been used in practice to conduct
an actual clinical trial. In this article, we focus on three of
the practical barriers to its use, namely: (1) insuﬃcient sta-
tistical power (when computed using traditional hypothesis
testing procedures); (2) the need for instantly observed treat-
ment outcomes; and; (3) a lack of randomization to provide a
basis for inference. To address these barriers, we propose the
forward looking Gittins index algorithm, a randomized group
sequential allocation procedure based on the index solution
to the classic inﬁnite horizon multi-arm bandit problem.
Simulations conﬁrm that the FLGI procedure, combined
with a protected control group allocation, enables adaptively
block-randomized clinical trials that are as follows: statisti-
cally conservative when no treatment with additional beneﬁt
over control exists; statistically powerful when one does; and
highly ethical in terms of patient beneﬁt. These characteris-
tics were found to persist when the block size was stochastic,
instead of being ﬁxed (results not shown). As with all adap-
tive allocation procedures, the feasibility of our approach is
diminished when there are signiﬁcant delays in observing pa-
tient responses.
The FLGI rule, although independently developed, resem-
bles the policy improvement algorithm (see e.g., Howard,
1960) used to approximate computational expensive opti-
mal value functions in Markov Decision problems. Semi-
randomized rules based on the Gittins index have been pro-
posed by Glazebrook (1980). These rules overcome the power
limitation by continuing to allocate suboptimal arm with a
positive, though decreasing, probability. However, they are
not expressed in terms of allocation probabilities, and thus do
not constitute a fully randomized procedure in the sense that
we have outlined here. Gittins indices and analogous optimal-
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Figure 3. The suboptimality gap for T = 80 and T = 417 as the population size varies in N = {(2, 3, 4, . . . , 11)T,
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simulations using the GI rule to make a ﬁnal decision for FLGI, CFLGI, and GI.
ity results have been derived for a variety of endpoints. There-
fore, a natural extension of this work can consider other end-
points, e.g., exponentially distributed populations (see Gittins
et al., 2011). Also, extending the FLGI rule for the case in
which covariates are available, as in Yang and Zhu (2002), is
very relevant.
Finally, the FLGI rule is especially useful for trials in which
the main goal is the selection of a superior treatment for con-
tinuing further study (for example in Phase II or rare dis-
ease settings). This is because the FLGI (just as the Gittins
Index) skews the allocation toward one of the treatments,
selecting the best treatment within the trial when it exists,
although it is often then unable to declare it eﬀective at the
desired signiﬁcance level. This highlights the need to develop
hypothesis testing procedures which complement bandit de-
signs. High power may be less relevant than the goal of having
a large probability of selecting a superior within the trial and
therefore treating patients better. If power is a concern, the
controlled FLGI rule can be applied to gain both power and
ethical advantages.
Adaptive designs are often criticized in terms of their fre-
quentist operating characteristics. We have found that the
FLGI approach controls the type one error conservatively and
that the suboptimal arms (those discarded within the trial by
the FLGI rule) also have their success rates slightly under-
estimated (Villar et al., 2015). Further research is needed to
develop testing and estimation procedures that maintain the
correct frequentist operating characteristics.
The motivation of our proposed algorithm was in the set-
ting of clinical trials, but its use is not limited to medical ap-
plications. The heuristic applies to sequential allocation prob-
lems more generally. In particular, the FLGI can be used as a
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heuristic to solve bandit problems with more than two actions
(See Web Appendix C and E) or with random block sizes.
6. Supplementary Web Appendix
Web Appendices A–D and additional Tables referenced in Sec-
tions 2, 3, 3.1, 4.2, 4.3, and 5 are available with this article
at the Biometrics website on Wiley Online Library. Example
code and instructions for running it are also available as a
web supplement (same website).
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